Brief: ABVC Biopharma Says Vitargus Phase II Study On Hold Due To Serious Adverse Events
09/06/2023 22:52
June 9 (Reuters) - ABVC Biopharma Inc ABVC.O :
* ABVC BIOPHARMA INC - VITARGUS PHASE II STUDY WAS PUT ON
HOLD DUE
TO SERIOUS ADVERSE EVENTS (SAES) OBSERVED IN PATIENTS
Further company coverage: ABVC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ABVC Biopharma
See all newsBrief: ABVC Biopharma - Quarterly Period Ended September, 2025 Financial Statements Should Not Be Relied Upon
Brief: Abvc Biopharma Inc Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: ABVC Biopharma Concluded That Financial Statements For FY Ended Dec 31, 2023 Should No Longer Be Relied Upon Due To Errors In Financial Statements
Brief: ABVC Biopharma Inc On March 5, Leeds Chow Resigns As CFO Of Abvc Biopharma
Brief: ABVC Biopharma Secures $200,000 In First Cash Licensing Payment From Oncology Products Partner